D. Shaffer

发表

Differential exoprotease activities confer tumor-specific serum peptidome patterns.

A. Olshen, C. Cordon-Cardo, J. Boyd, 2005, The Journal of clinical investigation.

Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate.

A. Viale, J. Satagopan, K. Manova, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

R. Bourgon, P. Hegde, T. Powles, 2017, The Lancet.

ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression

C. Blobel, V. Reuter, H. Scher, 2006, Oncogene.

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Jason A. Koutcher, Howard I. Scher, Pier Paolo Pandolfi, 2005, Nature.

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

P. Mischel, J. Teruya-Feldstein, H. Scher, 2009, Journal of Neuro-Oncology.

A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM).

L. Deangelis, H. Scher, N. Rosen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p27 deficiency desensitizes Rb−/− cells to signals that trigger apoptosis during pituitary tumor development

P. Pandolfi, C. Cordon-Cardo, D. Shaffer, 2003, Oncogene.

The men’s cycle plus docetaxel (Doc) in prostate cancer patients with rising PSAs in the non-castrate state

M. Morris, H. Scher, M. Carducci, 2005 .

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

M. Atkins, M. Fishman, E. Plimack, 2019, Cancer.

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

R. Motzer, J. Hsieh, E. Schmidt, 2020 .

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

M. Burotto, A. Armstrong, L. Lacombe, 2022, Journal for ImmunoTherapy of Cancer.

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, M. Burotto, D. Shaffer, 2021 .

Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion

W. Gerald, P. Pandolfi, W. Kuo, 2013, Nature Genetics.

Prostate cancer: a dynamic illness with shifting targets.

H. Scher, D. Shaffer, Howard I Scher, 2003, The Lancet. Oncology.

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

T. Powles, D. Shaffer, D. Petrylak, 2021, Clinical Cancer Research.

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

H. Scher, M. Leversha, H. Lilja, 2007, Clinical Cancer Research.

CirculatingTumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

H. Scher, M. Leversha, H. Lilja, 2007 .

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

R. Figlin, R. Motzer, M. Voss, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

J. Christensen, J. Rosenberg, D. Shaffer, 2020 .

Critical function for ADAM9 in mouse prostate cancer.

C. Blobel, V. Reuter, H. Scher, 2005, Cancer research.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

R. Figlin, R. Motzer, M. Voss, 2017 .

Breaking the rules of cancer

P. Pandolfi, D. Shaffer, 2006, Nature Medicine.

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J. Burke, A. Eisen, M. Kohli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC)

K. Pienta, D. Shaffer, L. Terstappen, 2007 .

Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.

A. Leiter, T. Sablinski, John Holland, 2017, JCO clinical cancer informatics.

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.

F. Saad, A. Armstrong, D. Shaffer, 2021, European journal of cancer.

Everolimus combined with gefitinib in patients with metastatic castration‐resistant prostate cancer: Phase 1/2 results and signaling pathway implications

S. Larson, M. Morris, H. Scher, 2015, Cancer.

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

S. Jain, R. Motzer, J. Hsieh, 2021, The Lancet. Oncology.

Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD

C. Drake, D. Shaffer, A. Saci, 2019, Annals of Oncology.

Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion

W. Gerald, P. Pandolfi, W. Kuo, 2013, Nature Genetics.

Digital Commons@Becker Digital

F. Saad, A. Ravaud, A. Armstrong, 2023 .

2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma

J. Burke, A. Eisen, M. Kohli, 2015 .